icn
Logo MY CLINIC
Doktor odb. as. Ing. Martin Meliška

odb. as. Ing. Martin Meliška

Biomedical engineer
BOOK YOUR SPECIALIST’S APPOINTMENT
Czech, English

Curriculum Vitae

Employment and expertise

2020 - present

MY CLINIC - Biomedical Engineer

2019 - present

Appointed as Head of Dept. of Optometrists in 2019, Department of Ophthalmology, First Faculty of Medicine, Charles University and General Teaching Hospital in Prague

2018 - present

Canadian medical Care - Biomedical Engineer

2017 - present

Assistant  professor; First Faculty of Medicine, Charles University

2017 - present

Axon Clinical - Biomedical Engineer in clinical research

2009 - present

Biomedical Engineer; Department of Ophthalmology, First Faculty of Medicine, Charles University and General Teaching Hospital in Prague

2000 - 2009

GPH Partners, Prague - Computer technician

Others

Main scientific activities and clinical research experience

Subinvestigator in clinical trials with anti-VEGF therapy, uveitis therapy and geographic atrophy therapy :

2013 - 2016

AbbVie s.r.o., M 10 877, M 10 880, M 11 327, sub-investigator

2013 - 2016

Sanofi, ACT 134 80, sub-investigator

2014 - 2015

phase 2, DREAM - Efficacy, safety, and tolerability of repeated topical doses od regorafenib eye drops, in treatment-naïve subjects with neovascular age-related macular degeneration, sub-investigator

2014 - 2016

phase 4, LUMINOUS, Observe the Effectiveness and Safety of Ranibizumab in Real Life Setting, sub-investigator

2011 - present

phase 3, PREDICT - Personalized Risk Evaluation and Diagnosis In the Coronary Tree, sub-investigator

2011 - 2014

phase 2, ORAYA - To determine if the IRay System is effective in sparing the number of Lucentis injections, sub-investigator

2009 - 2016

phase 4, AMADEuS - monitor patients diagnosed with the wet form of age related macular degeneration, sub-investigator

2016 - present

phase 3, Safety and Efficacy in Patients with Neovascular Age-related Macular Degeneration, sub-investigator

2016 - present

phase 3b, Efficacy, safety, and tolerability intravitreal injections using two different treatment regimens to subjects with neovascular age-related macular degeneration (nAMD), sub-investigator

2016 - present

phase 3, Efficacy  and  safety  of  the  biosimilar in  comparison  to  the  approved originator product in patients with neovascular age‐related macular degeneration, sub-investigator

2018 - present

phase 3, Single-Chain Antibody Fragment VEGF Inhibitor RTH258 for Neovascular Age-Related Macular Degeneration: A Randomized Controlled Study, sub-investigator

2019 - present

phase 3, Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular Age-related Macular Degeneration, sub-investigator

2019 - present

phase 3, Efficacy and Safety Trial treatments of Diabetics Macular Edema, sub-investigator

2020 - present

phase 3, Studies of the Targeted C3 Therapy, Pegcetacoplan, in Patients with Geographic Atrophy (GA), sub-investigator

GCP TRAINING

GCP including ICH E6, Revision 2 Changes, GCP training done during investigator’s meeting of each study
 

 

Education

2004 - 2007

Bc. (Bachelor Study), Czech Technical University in Prague, The Faculty of Biomedical Engineering specialisation: Medical Devices, Czech Republic

2007 - 2009

Ing. (Master Study), Czech Technical University in Prague, The Faculty of Biomedical Engineering specialisation: Systematic Integration of  Processes in Health Service, Czech Republic

2009 - 2015

Electrotechnical qualification 50, § 6,7,8,10

2015

Electrotechnical qualification for profession biomedical engineer, Czech Technical University in Prague, The Faculty of Biomedical Engineering

2015

Accredited qualification course Biomedical Engineering, Institute of  Postgraduate Medical Education in Prague

Publications

11 impact factor journal articles (co-author)
Paraproteinemic keratopathy associated with monoclonal gammopathy of undetermined significance (MGUS): clinical findings in twelve patients including recurrence after keratoplasty.

Review of SRD5A3 Disease-Causing Sequence Variants and Ocular Findings in Steroid 5α-Reductase Type 3 Congenital Disorder of Glycosylation, and a Detailed New Case.

Clinical and genetic determinants of chronic visual pathway changes after methanol - induced optic neuropathy: four-year follow-up study.

Peripapillary microcirculation in Leber hereditary optic neuropathy.

Progressive Chronic Retinal Axonal Loss Following Acute Methanol-induced Optic Neuropathy: Four-Year Prospective Cohort Study.

OCT Findings and Long-term Follow-up Results of Vitrectomy in Patients with Optic Disc Pit and Associated Maculopathy.
 

Active participation in undergraduate education

Undergraduate teaching of Medical devices in Ophthalmology to students of the First Faculty of Medicine, Charles University

Curriculum Vitae

Education

2004 - 2007

Bc. (Bachelor Study), Czech Technical University in Prague, The Faculty of Biomedical Engineering specialisation: Medical Devices, Czech Republic

2007 - 2009

Ing. (Master Study), Czech Technical University in Prague, The Faculty of Biomedical Engineering specialisation: Systematic Integration of  Processes in Health Service, Czech Republic

2009 - 2015

Electrotechnical qualification 50, § 6,7,8,10

2015

Electrotechnical qualification for profession biomedical engineer, Czech Technical University in Prague, The Faculty of Biomedical Engineering

2015

Accredited qualification course Biomedical Engineering, Institute of  Postgraduate Medical Education in Prague

Employment and expertise

2020 - present

MY CLINIC - Biomedical Engineer

2019 - present

Appointed as Head of Dept. of Optometrists in 2019, Department of Ophthalmology, First Faculty of Medicine, Charles University and General Teaching Hospital in Prague

2018 - present

Canadian medical Care - Biomedical Engineer

2017 - present

Assistant  professor; First Faculty of Medicine, Charles University

2017 - present

Axon Clinical - Biomedical Engineer in clinical research

2009 - present

Biomedical Engineer; Department of Ophthalmology, First Faculty of Medicine, Charles University and General Teaching Hospital in Prague

2000 - 2009

GPH Partners, Prague - Computer technician

Others

Main scientific activities and clinical research experience

Subinvestigator in clinical trials with anti-VEGF therapy, uveitis therapy and geographic atrophy therapy :

2013 - 2016

AbbVie s.r.o., M 10 877, M 10 880, M 11 327, sub-investigator

2013 - 2016

Sanofi, ACT 134 80, sub-investigator

2014 - 2015

phase 2, DREAM - Efficacy, safety, and tolerability of repeated topical doses od regorafenib eye drops, in treatment-naïve subjects with neovascular age-related macular degeneration, sub-investigator

2014 - 2016

phase 4, LUMINOUS, Observe the Effectiveness and Safety of Ranibizumab in Real Life Setting, sub-investigator

2011 - present

phase 3, PREDICT - Personalized Risk Evaluation and Diagnosis In the Coronary Tree, sub-investigator

2011 - 2014

phase 2, ORAYA - To determine if the IRay System is effective in sparing the number of Lucentis injections, sub-investigator

2009 - 2016

phase 4, AMADEuS - monitor patients diagnosed with the wet form of age related macular degeneration, sub-investigator

2016 - present

phase 3, Safety and Efficacy in Patients with Neovascular Age-related Macular Degeneration, sub-investigator

2016 - present

phase 3b, Efficacy, safety, and tolerability intravitreal injections using two different treatment regimens to subjects with neovascular age-related macular degeneration (nAMD), sub-investigator

2016 - present

phase 3, Efficacy  and  safety  of  the  biosimilar in  comparison  to  the  approved originator product in patients with neovascular age‐related macular degeneration, sub-investigator

2018 - present

phase 3, Single-Chain Antibody Fragment VEGF Inhibitor RTH258 for Neovascular Age-Related Macular Degeneration: A Randomized Controlled Study, sub-investigator

2019 - present

phase 3, Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular Age-related Macular Degeneration, sub-investigator

2019 - present

phase 3, Efficacy and Safety Trial treatments of Diabetics Macular Edema, sub-investigator

2020 - present

phase 3, Studies of the Targeted C3 Therapy, Pegcetacoplan, in Patients with Geographic Atrophy (GA), sub-investigator

GCP TRAINING

GCP including ICH E6, Revision 2 Changes, GCP training done during investigator’s meeting of each study
 

Publications

11 impact factor journal articles (co-author)
Paraproteinemic keratopathy associated with monoclonal gammopathy of undetermined significance (MGUS): clinical findings in twelve patients including recurrence after keratoplasty.

Review of SRD5A3 Disease-Causing Sequence Variants and Ocular Findings in Steroid 5α-Reductase Type 3 Congenital Disorder of Glycosylation, and a Detailed New Case.

Clinical and genetic determinants of chronic visual pathway changes after methanol - induced optic neuropathy: four-year follow-up study.

Peripapillary microcirculation in Leber hereditary optic neuropathy.

Progressive Chronic Retinal Axonal Loss Following Acute Methanol-induced Optic Neuropathy: Four-Year Prospective Cohort Study.

OCT Findings and Long-term Follow-up Results of Vitrectomy in Patients with Optic Disc Pit and Associated Maculopathy.
 

Active participation in undergraduate education

Undergraduate teaching of Medical devices in Ophthalmology to students of the First Faculty of Medicine, Charles University

Book your doctor’s appointment